pdf   xlsx method abbreviations

la/mBC - HR-positive - 2nd line (L2), tucidinostat based treatment , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

progression or deaths (PFS) 0.75 [0.58, 0.97]< 10%1 study (1/-)98.4 %NAnot evaluable important-
CBR 1.59 [1.02, 2.49]> 10%1 study (1/-)97.9 %NAnot evaluable non important-
DOR 1.43 [0.41, 4.96]< 10%1 study (1/-)28.7 %NAnot evaluable non important-
objective responses (ORR) 2.26 [1.12, 4.55]> 10%1 study (1/-)98.9 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.